SCHEMBL21200593

SCHEMBL21200593

Cn1cnnc1C(F)(F)[C@](C)(F)c1cccc(NC(=O)c2cc(CN3CC[C@H](F)C3)nc(C3CC3)n2)c1

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21200595 1.00 CBLB (0.74) CBLB
SCHEMBL29867089 1.00 CBLB (0.74) CBLB
SCHEMBL21212207 0.86 CBLB (1.00) CBLB
SCHEMBL29866823 0.86 CBLB (1.00) CBLB
SCHEMBL21200205 0.77 CBLB (0.75) CBLB
SCHEMBL29866905 0.77 CBLB (0.75) CBLB
SCHEMBL21200202 0.77 CBLB (0.75) CBLB
SCHEMBL29998839 0.76 CBLB (0.54) CBLB
SCHEMBL29998745 0.76 CBLB (0.54) CBLB
SCHEMBL29998604 0.76 CBLB (0.54) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback